Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6246675 | 0.91 | HDAC6 (0.72) | HDAC6MEN1RAB9AKMT2APOLB | |
| SCHEMBL18573454 | 0.86 | HDAC6 (0.55) | HDAC6MEN1RAB9AKMT2AALDH1A1 | |
| SCHEMBL3086968 | 0.84 | HDAC6 (0.85) | HDAC6MEN1RAB9AKMT2AALDH1A1 | |
| SCHEMBL18573642 | 0.82 | NPC1 (0.63) | HDAC6MEN1RAB9AKMT2AALDH1A1 | |
| SCHEMBL18573453 | 0.80 | RAB9A (0.60) | HDAC6MEN1RAB9AKMT2AHPGDS | |
| SCHEMBL12900103 | 0.80 | FABP3 (0.53) | HDAC6MEN1RAB9AKMT2AALDH1A1 | |
| SCHEMBL18573590 | 0.77 | NPC1 (0.62) | HDAC6MEN1RAB9AKMT2AALDH1A1 | |
| SCHEMBL3098138 | 0.75 | HDAC6 (1.00) | HDAC6MAPTTP53 | |
| SCHEMBL23035052 | 0.75 | HDAC1 (0.57) | HDAC6RAB9AALDH1A1MAPK1MAPT | |
| SCHEMBL19721202 | 0.75 | HPGD (0.64) | HDAC6RAB9AALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3339299-B1 | NOVEL CATECHOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AUTOPHAGYSCIENCES INC (KR) | 2021-03-03 | — | — | EP | claimed |
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-07-02 | — | — | US | claimed |
| EP-1828177-B1 | NOVEL MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1828177-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006066173-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | claimed |
| US-7838543-B2 | Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles | ELI LILLY AND COMPANY (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-07-02 | — | — | US | disclosed |
| EP-1828177-B1 | NOVEL MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1828177-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066173-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20050209284-A1 | Tec kinase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005079791-A1 | THIOPHENE -2- CARBOXYLIC ACID - (1H - BENZIMIDAZOL - 2 YL) - AMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE TEC KINASE ITK (INTERLEUKIN -2- INDUCIBLE T CELL KINASE) FOR THE TREATMENT OF INFLAMMATION, IMMUNOLOGICAL AND ALLERGIC DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170913-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | HDAC6 1723/4885MEN1 550/4885RAB9A 1154/4885 |
| US-20050209284-A1 | Tec kinase inhibitors | TEC, ITK, TXK | HDAC6 894/4885MEN1 3793/4885RAB9A 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.